ALLO News and Press, Allogene Therapeutics Inc. From 01/04/21

A Phase 1 Chinese biotech developing CAR-T cell therapies for cancer, Gracell Biotechnologies (GRCL) to raise $150M by offering 8.825M ADSs at a price range of $16 to $18.Underwriters' over-allotment is an additional 1,323,750 ADSs.Net proceeds together with existing cash and cash equiva...

Allogene Therapeutics ([[ALLO]] +0.0%) announced that the U.S. FDA has cleared an Investigational New Drug application to study ALLO-715 in combination with nirogacestat, SpringWorks Therapeutics’ investigational gamma secretase inhibitor, in patients with relapsed or re...

Allogene Therapeutics (ALLO) announced that the FDA has cleared its Investigational New Drug application to study ALLO-715 in combination with nirogacestat for the treatment of relapsed or refractory multiple myeloma.ALLO-715, an AlloCAR T therapy targeting BCMA (B-cell maturation a...

Combination Represents One of Allogene’s Three Strategies to Target BCMA for Multiple Myeloma Phase 1 Clinical Trial Expected to Begin in the First Quarter of 2021 SOUTH SAN FRANCISCO, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a...

Gracell Biotechnologies has filed to raise $100 million in a U.S. IPO, although the final figure may vary. The firm is developing treatments for various cancers using a CAR-T approach. GRCL has produced very promising Phase 1 trial results for its lead candidate. For further...

Overland Pharmaceuticals will form a $117 million China JV with Allogene Therapeutics to bring allogenic CAR-T drugs to China. Harbour BioMed has out-licensed its fully human SARS-CoV-2 neutralizing antibody, 47D11, to AbbVie. Legend Biotech was cleared to start a US Phase I trial...

Allogene is a leader in its space, allogeneic CAR-T targeting mainly hematologic malignancies. The company is flush with cash. If successful, this company could be a major winner. For further details see: Allogene: Cutting Edge Allogeneic CAR-T Therapy Developer

Allogene Therapeutics (ALLO) up 5% in premarket and Overland Pharmaceuticals have joined to form Allogene Overland Biopharm, a joint venture focused on the development, manufacturing and commercialization of therapy for blood cancers and solid tumors in China, Taiwan, South Kor...

Allogene Overland Biopharm, a First-of-its-Kind Collaboration in Allogeneic Cell Therapy, Is Dedicated to Making AlloCAR T™ Available to Patients in Greater China, Taiwan, South Korea and Singapore The Joint Venture Provides An Opportunity to Accelerate the Global Development o...

The following slide deck was published by Allogene Therapeutics, Inc. in conjunction with this event. For further details see: Allogene Therapeutics (ALLO) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow